Clinical Trials Logo
NCT number NCT01985126
Study type Interventional
Source Janssen Research & Development, LLC
Contact
Status Active, not recruiting
Phase Phase 2
Start date September 2013
Completion date October 2016

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of 2 daratumumab treatment regimens in participants with multiple myeloma who have received at least 3 prior lines of therapy (including a proteasome inhibitor [PI] and immunomodulatory drug [IMiD]) or are double refractory to a PI and an IMiD.


Clinical Trial Description

This is an open-label (identity of assigned study drug will be known) study of daratumumab for the treatment of participants with multiple myeloma who have received at least 3 prior lines of therapy including a PI and an IMiD or whose disease is double refractory to both a PI and an IMiD. Up to approximately 150 participants are to be enrolled. The study includes screening, treatment, and follow-up phases. Participants will receive daratumumab by intravenous infusion (28-day cycles) until disease progression, unacceptable toxicity, or other protocol-defined reasons. For all study drug administrations, participants will receive pre- and post-infusion medications for the prevention of infusion related reactions. Follow-up will continue until death, loss to follow up, consent withdrawal for study participation, or study end, whichever occurs first. The study will consist of 2 sequential parts (Part 1 and Part 2). The purpose of Part 1 is to select a dose and schedule for Part 2 of the study. Assessment of tumor response and disease progression will be conducted according to IMWG response criteria. Serial pharmacokinetic blood samples and a pharmacogenomic blood sample will be collected. Safety will be monitored throughout the study. At the end of the study, participants who are benefiting from treatment with daratumumab will have the option to continue treatment.


Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


See also
Status Clinical Trial Phase
 Recruiting NCT02976272 - Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple N/A
 Recruiting NCT02916420 - Efficacy and Safety of Pomalidomide in Combination With Low-dose Dexamethasone in Chinese Patients With Relapsed and Refractory Multiple Myeloma Phase 3
 Recruiting NCT02918331 - A Study of JNJ-54767414 (Daratumumab) in Combination With Lenalidomide and Dexamethasone in Japanese Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy and Autologous Stem Cell Transplantation Phase 1
 Recruiting NCT02852837 - Dose Escalation Study of JNJ-54767414 (Daratumumab) in Chinese Participants With Relapsed or Refractory Multiple Myeloma Who Failed at Least 2 Prior Lines of Systemic Therapy Phase 1
 Recruiting NCT02843074 - Elotuzumab, Lenalidomide and Dexamethasone (ERd) in the Induction, Consolidation and Maintenance Treatment of Transplant-Eligible, Newly Diagnosed Multiple Myeloma Patients Phase 2
 Recruiting NCT02909036 - Study of Captisol Enabled Melphalan and Pharmacokinetics for Patients With Multiple Myeloma or Light Chain Amyloidosis That Are Receiving an Autologous Transplant. Phase 1
 Recruiting NCT02812706 - Isatuximab Single Agent Study in Japanese Relapsed AND Refractory Multiple Myeloma Patients Phase 1/Phase 2
 Recruiting NCT02811978 - Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma Phase 3
 Available NCT02856438 - Early Patient Access Treatment Use Protocol CA204-220 N/A
 Not yet recruiting NCT02863991 - Oral ONC201 in Relapsed/Refractory Multiple Myeloma Phase 2
 Not yet recruiting NCT02892383 - Quality of Life the Danish Multiple Myeloma Patients N/A
 Not yet recruiting NCT02898064 - Back Pain Prevention in Multiple Myeloma Using an External Spinal Brace N/A
 Not yet recruiting NCT02757326 - ABC294640 in Refractory / Relapsed Multiple Myeloma Phase 1/Phase 2
 Recruiting NCT02384083 - Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients Phase 1/Phase 2
 Recruiting NCT02506959 - Panobinostat Combined With High-Dose Gemcitabine/Busulfan/Melphalan With Autologous Stem Cell Transplant for Patients With Refractory/Relapsed Myeloma Phase 2
 Recruiting NCT02575144 - GEM-CLARIDEX: Ld vs BiRd Phase 3
 Recruiting NCT02902900 - An Efficacy Study of Pomalidomide in Patient With Multiple Myeloma in Routine Clinical Practice N/A
 Recruiting NCT02507479 - Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies Phase 2
 Recruiting NCT02499081 - UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment Phase 2
 Recruiting NCT02541383 - A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma Phase 3